Citations

Clear

572 citation(s) found for "Silva, P".

Cardiac magnetic resonance imaging parameters predict new-onset symptoms of heart failure in hypertrophic cardiomyopathy
Silva, Danuzia Santana da, Vizentin, Vanessa Karlinski , Maanja, Maren , Lahori, Simmy A, Ommen, Steve, Geske, Jeffrey B, Giudicessi, John R, Araoz, Philip A. , Ackerman, Michael J, Arruda‐Olson, Adelaide M. , Bos, J. Martijn , da Silva, Danuzia S, Félix, Iuri Ferreira , Bos, Johan M , Lahori, Simmy , Pasupathy, Kalyan S. , Ommen, Steve R. , Geske, Jeffrey B. , Giudicessi, John R. , Ackerman, Michael J.

Mayo Clinic

ESC Heart Failure | June 6, 2026 | Volume: 13 | Issue: 3 | Pages: No page available

10.1093/eschf/xvag160 | PMID 42263198 Get It

Abstract Background Hypertrophic cardiomyopathy (HCM) is a heritable cardiac disorder characterized by increased left ventricular (LV) wall thickness, often leading to heart failure (HF). The role of cardiovascular magnetic resonance (CMR) imaging in predicting new onset of HF symptoms in patients with HCM remains unknown. This study aimed to identify CMR predictors of new-onset HF symptoms in individuals with HCM. Methods This study was a single-centre retrospective cohort study of HCM patients treated at a tertiary referral centre in the USA who underwent CMR examination between 1998 and 2018, had no HF symptoms at baseline CMR, and at least 1 year of follow-up. Clinical data were collected by review of electronic medical records, and CMR images were analyzed by a blinded expert cardiac radiologis. The primary outcome was new onset of HF symptoms, defined as New York Heart Association (NYHA) class ≥ II at follow-up. Kaplan–Meier analyses and Cox proportional hazard analyses were performed. Results Of 1462 patients diagnosed with HCM who had at least 1 CMR, 276 HCM patients without HF symptoms (average age 52.7 years, 33.3% female),median maximum left ventricular (LV) wall thickness was 19 mm ([IQR] 17–22) with a and median LV ejection fraction of 71% (IQR 66–77). Late gadolinium enhancement was detected in 56.2%) patients (60.7% had mild; 30.7% moderate; 8.6% severe). During a median follow-up period of 6.3 years, 93 patients developed HF symptoms (NYHA class II in 56 (60.2%); class III in 31 (33.3%); and class IV in 6 (6.5%). Multivariable analysis adjusted for age showed that LA enlargement (HR 1.626; 95% CI 1.01–2.62; P = .045) and LV mass index (HR 1.014; 95% CI 1.007–1.022; P≤ .001) and sex (HR 1.7; 95% CI 1.074–2.691; P = .023) were independent predictors of new onset of HF symptoms in patients with HCM. Conclusions Nearly half of the patients with HCM developed HF symptoms within 6.3 years. Left atrial enlargement, LV mass index, and sex were independent predictors of new onset of HF symptoms in HCM patients. These findings emphasize the value of CMR in HF risk stratification.
EGFR INHIBITION PROMOTES ENTEROENDOCRINE CELL DIFFERENTIATION CONTRIBUTING TO TREATMENT-ASSOCIATED DIARRHEA
Ramos, Guilherme Piovezani , Zeve, Daniel , Shepherd, Amy , Saint-Denis, Elisa, Aldefer, Olivia, Frintu, Bia, Dale, Stanley, Sharma, Karina, Mohlmann, Emma , Mannam, Prabhath , Byers, Morgan , Terzian, Jack, Ribeiro, Claudio D , Borges, Kleiton S., Carlone, Diana , Rao, M Prasada, Zeve, Daniel , Ribeiro, Claudio , Oliveira, Luiz Fernando , Borges, Kleiton Silva , O'Connell, Amy E , Carlone, Diana L , Duma, Narjust , Rao, Meenakshi , Breault, David T , Ramos, Guilherme P , Shepherd, Amy , Saint‐Denis, Elisa, Frintu, Bianca, Sharma, Karina, O’Connell, Amy E. , Florez, Narjust

Mayo Clinic

No container title available | June 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.02.729650 | PMID 42282735 Get It

ABSTRACT Enteroendocrine cells (EECs) are specialized sensors of the gastrointestinal (GI) epithelium that regulate gut function and systemic metabolism through hormone secretion. The molecular pathways directing intestinal stem cell (ISC) differentiation into EECs are incompletely understood due, in part, to their rarity. We sought to identify novel regulators of human EEC differentiation using a high-throughput screen of FDA-approved drugs and human duodenal organoids. Two epidermal growth factor receptor inhibitors (EGFRi) commonly used in cancer therapy and known to cause GI side effects, erlotinib and lapatinib, emerged as strong inducers of EEC differentiation, dramatically increasing chromogranin A (CHGA) expression compared to controls, while maintaining ISC function and organoid growth. EGFRi-treated organoids revealed robust and broad upregulation of EEC hormones, including serotonin (5HT), motilin (MLN), and somatostatin (SST), among others. In agreement with these findings, analysis of a patient cohort with lung cancer revealed an association with erlotinib use and increased circulating levels of the above EEC hormones compared to matched controls. Supporting a direct effect of EGFRi on EEC differentiation, mice treated with erlotinib demonstrated increased EEC numbers and hormones and showed EGFRi-associated diarrhea (EAD), a limiting side effect of these medications. Mechanistically, EGFRi induced upregulation of interferon (IFN) signaling targets during early ISC-to-EEC differentiation. Consistent with this, inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) attenuated EGFRi-induced EEC differentiation. These findings provide important insight into EEC differentiation that could inform treatment strategies for EAD, metabolic diseases, and GI diseases. Brief Summary Inhibition of EGFR signaling promotes human ISC-to-EEC differentiation through activation of STAT1 signaling.
Safety of esophageal endoscopic submucosal dissection of Barrett’s esophageal neoplasia: an analysis of factors associated with stricture formation
Omae, M, Isacsson, N Hentati, Maltzman, H, Mathieu, P, Moll, F, Bourke, M J, Gupta, S, Ebigbo, A, Roser, D A, Deprez, P, Maximilien, B, Wang, K K, Leggett, C L, Koch, A D, Maan, AD I, Baldaque-Silva, F, Omae, Masami , Isacsson, Nils Hentati , Maltzman, Henrik , Moll, Frederic C., Bourke, Michael J. , Ebigbo, Alanna , Barret, Maximilien , Leggett, Cadman L. , Baldaque‐Silva, Francisco

Mayo Clinic

Endoscopy | June 5, 2026 | Volume: 58 | Issue: S 03 | Pages: S107-S108

10.1055/s-0046-1820814 Get It

Dose-dependent white matter changes associated with repetitive head impacts in former American football players
Arciniega, Hector , Wickham, Alana, Szekely, Brian, Kim, Nicholas, Cho, Kang I, Carrington, Holly, Knyazhanskaya, Evdokiya , John, Omar , Jung, Leonard , Breedlove, Katherine M. , Mirmajlesi, Anya S, Stearns, Jared, Rushmore, R Jarrett, Daneshvar, Daniel H, Wiegand, Tim L T, Billah, Tashrif , Pasternak, Ofer, Cetin-Karayumak, Suheyla, Rathi, Yogesh, Coleman, Michael J, Bernick, Charles, Balcer, Laura J, Im, Brian , Datta, Shae , Alosco, Michael L. , Lin, Alexander P, Cummings, Jeffrey L, Reiman, Eric M, Stern, Robert A, Shenton, Martha E, Bouix, Sylvain, Su, Yi, Chen, Kewei, Protas, Hillary, Boker, Connie, Au, Rhoda, Cantu, Robert C, Farrer, Lindsay, Helm, Robert, Katz, Douglas I, Kowall, Neil, Mez, Jesse, Mercier, Gustavo, Otis, James, Weller, Jason, Simkin, Irene, Andino, Alondra, Conneely, Shannon, Diamond, Courtney, Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen, Nanna, Mary, Platt, Taylor, Rice, Fiona, Sestak, Madison, McClean, Michael, Tripodis, Yorghos, Annis, Douglas, Chaisson, Christine, Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Lu, Jun, Martin, Brett, Ojo, Emmanuel, Palmisano, Joseph N, Pine, Brittany, Ramachandran, Janani, Fitzsimmons, Jennifer, Arcinieago, Hector, Bonke, Elena, Coello, Eduardo , Jung, Leonhard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah, Miller, Jason, Ritter, Aaron , Sabbagh, Marwan, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Dodick, David W, Geda, Yonas, Wethe, Jennifer V, Falk, Bryce, Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Bellgowan, Patrick, Balcer, Laura, Barr, William, GOLDBERG, JUDITH, Wisniewski, Thomas, Kirov, Ivan, Lui, Yvonne, Marmar, Charles, Hasanaj, Lisena, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan, Martin, Sammie, Riley, Edward, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth , Marcus, Daniel S, Gurney, Jenny , Greenwald, Richard, Johnson, Keith A, Wethe, Jennifer V. , Wiegand, Tim L. T. , Jung, Leonard B , Breedlove, Katherine , Stearns, Jared , Adler, C H , Alosco, Michael L , Koerte, Inga K , Wethe, Jennifer V , Arciniega, Hector , Kim, Nicholas , Carrington, Holly , Rushmore, R. Jarrett , Daneshvar, Daniel H. , Pasternak, Ofer , Karayumak, Suheyla Cetin , Rathi, Yogesh , Coleman, Michael J. , Adler, Charles H. , Bernick, Charles , Balcer, Laura J. , Reiman, Eric M. , Shenton, Martha E. , Bouix, Sylvain , Protas, Hillary , Cantu, Robert C. , Katz, Douglas I. , Mez, Jesse , Weller, Jason , Fagle, Tessa, Mariani, Megan, McLaughlin, Kathleen , Pulukuri, Surya Vamsi , Sestak, Madison, McClean, Michael D , Tripodis, Yorghos , Annis, Douglas, Finney, Carolyn, Palmisano, Joseph , Pine, Brittany, Ramachandran, Janani , Bonke, Elena M. , Liao, Huijun, II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Howard, Marci, Montague, Michelle, Babcock, Debra, Bellgowan, Patrick S.F. , Barr, William , Kirov, Ivan, George, Allan, Colasurdo, Elizabeth A. , Marcus, Daniel S., Johnson, Keith A.

Mayo Clinic

Brain Communications | May 29, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1093/braincomms/fcag195 | PMID 42293319 Get It

Abstract Repetitive head impacts sustained during American football have been associated with neuropathological changes such as white matter shear injuries. However, the impact of specific factors, such as age of first exposure and cumulative head impact burden, on white matter integrity remains unclear. This study investigated in vivo white matter microstructural changes using diffusion tensor imaging and tract-based spatial statistics in 165 male former American football players (mean age 57.3 years, range 45–74) and 52 unexposed asymptomatic male controls (mean age 59.4 years, range 45–74) in the DIAGNOSE CTE Research Project. Compared to controls, former football players exhibited significantly higher fractional anisotropy (FA) in 1.97% of the white matter skeleton (1552 voxels; Cohen’s d = 0.587) and higher tissue-corrected FA (FAt) in 1.48% of the white matter skeleton (1004 voxels; Cohen’s d = 0.616). No significant differences were observed for mean diffusivity, axial diffusivity, radial diffusivity, or free water between football players and controls. Among football players, there were no significant differences in the white matter microstructure between players diagnosed with traumatic encephalopathy syndrome and those without the diagnosis. Lower FA was significantly associated with older age (P < 0.00001) and an earlier age of first exposure to tackle football (P < 0.01), while lower FAt was associated with greater cumulative head impact burden, specifically higher linear acceleration (P < 0.04) and rotational force (P < 0.02). This study highlights the influential role of exposure factors on white matter microstructure in former American football players, as well as the utility of diffusion tensor imaging to aid in characterizing the long-term effects of repetitive head impacts in contact sport athletes.
Divergence between progression-free and overall survival treatment effect sizes in antibody-drug conjugate trials: A meta-epidemiologic study.
Melo, Andreia Cristina de, Almeida, L.F.C. de, Cappellaro, Anelise Poluboiarinov , Noronha, Mariana Macambira , Trapani, Dario, Silva, Jesse Lopes da, Melo, Andréia Cristina de , Conceição, Lucas Diniz da , Tarantino, Paolo , Batalini, Felipe

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e13076 Get It

e13076 Background: Progression-free survival (PFS) is frequently used as a primary endpoint in contemporary oncology trials, including antibody–drug conjugate (ADC) studies in metastatic breast cancer (MBC) settings, despite uncertainty regarding its validity as a surrogate for overall survival (OS). A meta-epidemiological analysis was performed to quantify the systematic differences between the treatment effects on PFS and OS in ADC randomized clinical trials (RCTs). Methods: Phase II–III ADC RCTs with MBC patients reporting hazard ratios (HRs) with 95% confidence intervals (CIs) for both progression-free survival (PFS) and overall survival (OS) were included. Differences in treatment effects within each trial were quantified using the ratio of hazard ratios (rHR = HR_PFS/HR_OS). Random-effects models were used to pool the rHRs across the trials. Prespecified subgroup and meta-regression analyses were used to evaluate the trial characteristics, clinical context, and regulatory status. Sensitivity analyses assessed the robustness across varying assumptions of the within-trial correlation between the endpoints. Results: Twenty-one RCTs evaluating nine ADCs in patients with MBC were included, comprising three phase II (14%) and 18 phase III (86%) studies. The pooled rHR demonstrated significantly larger treatment effects for PFS than for OS (rHR, 0.79; 95% CI, 0.73–0.86), with no between-trial heterogeneity (I² = 0%, τ² = 0). Sensitivity analyses assuming within-trial correlations between PFS and OS ranging from 0 to 0.95 yielded consistent results. Greater divergence between endpoints was observed in trials enrolling patients with triple-negative breast cancer (rHR, 0.72; 95% CI, 0.61–0.85) and HER2-low disease (rHR, 0.77; 95% CI, 0.62–0.96). Phase III trials showed larger differences than phase II trials (rHR, 0.79 vs. 0.89). When OS was a secondary endpoint, divergence was greater than when OS was primary (rHR, 0.77 vs. 0.87). Across trials, 16 of 21 studies (76%) demonstrated concordant effect directions between PFS and OS: 11 (52%) with a statistically significant benefit for both endpoints and 5 (24%) with neither endpoint significant. Discordance occurred in five trials (24%), all characterized by a statistically significant PFS benefit without a corresponding OS improvement. No trial demonstrated an OS benefit in the absence of a PFS benefit. Conclusions: Across ADC trials, PFS systematically overestimated OS treatment effects, underscoring the limitations of PFS as a standalone surrogate endpoint. These findings support the cautious interpretation of PFS-driven efficacy and reinforce the need for endpoint validation frameworks tailored to the mechanism, disease context, and trial design.
ADAPT-M: A tool to predict individualized benefit from adjuvant anti–PD-1 (PD-1) in resected high-risk melanoma.
Silva, Ines Esteves Domingues Pires da, Puig, S, Malvehy, Josep, Lebbe, Celeste, Meda, Laetitia Da , Leiter, Ulrike M., Vincent, T., Kaehler, Katharina C., Nalabothu, Rishitha, Khaddour, Karam , Huerta, Luis Paul Del Carpio, Grynberg, Shirly , Carlino, M S, Adegoke, Nurudeen A., Menzies, A, Long, Georgina V., Long, Georgina V. , Long, Georgina V , Grynberg, Shirly , Puig, Susana , Malvehy, Josep , Podlipnik, Sebastián , Stoff, Ronen , Hieken, Tina J. , Lebbé, Célèste , Leiter, Ulrike , Ma, Vincent The-Luc , Boutros, Andrea , Carpio, L.P. del , Carlino, Matteo S. , Menzies, Alexander M

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 9567-9567

10.1200/jco.2026.44.16_suppl.9567 Get It

9567 Background: Resected stage IIB/C and microscopic stage IIIA/B/C/D melanoma presents a significant risk of recurrence risk of 37 to 62% at 5 years (yrs). While 1 year of adjuvant PD1 therapy reduces this risk by approximately half, the individual patient’s baseline risk without treatment and their specific benefit from adjuvant PD1 remain unknown. We aimed to generate two separate predictive models for recurrence – one for untreated and one for treated pts - to calculate the individualised benefit of adjuvant PD1. Methods: Pts with resected stage IIB/C or microscopic stage IIIA/B/C/D melanoma, either treated with adjuvant PD1 or untreated at 13 major melanoma centres, and with at least 2 years of follow-up from surgery were included. We analysed pts demographics, disease characteristics, blood parameters, pathological and imaging data at baseline, and clinical outcomes. Propensity scores were estimated using logistic regression with covariates associated with treatment in univariate screening (p<0.05). Separate penalised multivariable logistic regression models were built to predict recurrence for treated and untreated pts. A tool based on these models was created to calculate the individual patient benefit from adjuvant PD1. Results: A total of 3560 pts was included, divided into untreated (discovery n=2384 and validation n=597) and treated (discovery n=404 and validation n=175) cohorts. The model for untreated pts included age, gender, primary site, histological subtype, Breslow thickness, ulceration, mitosis, number and site of regional lymph nodes (LN), mutation status and LDH (AUC 0.70 in discovery, 0.69 in validation). The model for treated pts included age, gender, Breslow thickness, site of regional LN, and mutation status (AUC 0.69 in discovery, 0.61 in validation). ADAPT-M (ADjuvant Anti-PD-1 Tool for Melanoma) calculates the individualized benefit of adjuvant PD1. For example, patient A, a woman ≤45 years old with a primary head & neck melanoma (superficial spreading, thickness >1-2 mm, no ulceration, 1 mitosis/mm 2 ), 2 clinically occult LN metastases in the neck, NRAS mutant, and normal LDH, has a 12-month recurrence risk of 21.9% untreated vs 2.3% treated (benefit 19.6%), and a 24-month risk of 41.1% untreated vs 6.4% treated (benefit 34.7%). While, patient B, a man ≤45 years old with a primary melanoma in the lower limb (nodular, thickness >1-2 mm, no ulceration, 1 mitosis/mm 2 ), 2 clinically occult LN metastases in the groin, BRAF V600 mutant, and normal LDH, has a 12-month recurrence risk of 14.2% untreated vs 11.8% treated (benefit 2.5%), and a 24-month risk of 28.0% untreated vs 30.1% treated (no benefit). Conclusions: ADAPT-M, a clinical tool that estimate individualized recurrence risks with and without adjuvant anti-PD1 therapy, quantifies the absolute benefit of treatment for pts with high-risk resected melanoma, facilitating personalized adjuvant therapy decisions.
Anti–PD-1 (PD-1) monotherapy versus combination with anti–CTLA-4 for metastatic uveal melanoma (MUM) patients (pts).
Silva, Ines Esteves Domingues Pires da, Grynberg, Shirly , Forschner, Andrea , Vincent, T., Liddle, Conner, Hopkins, Sam , Steinkerchner, Megan, Khaddour, Karam , Huerta, Luis Paul Del Carpio, Win, Su, Gebhardt, Christoffer , Hans, Tasvinder Kaur, Carlino, M S, Block, Matthew S. , Menzies, A, LO, S, Long, Georgina V., Long, Georgina V. , Lo, Serigne , Long, Georgina V , Lo, Serigne N , Grynberg, Shirly , Stoff, Ronen , Ma, Vincent The-Luc , Steinkerchner, Megan S. , Weichenthal, Michael , Carpio, L.P. del , Boutros, Andrea , Carlino, Matteo S. , Menzies, Alexander M

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 9535-9535

10.1200/jco.2026.44.16_suppl.9535 Get It

9535 Background: MUM carries a poor prognosis with few effective treatments, especially for HLA-A*02:01-negative pts. While a subset of MUM pts responds to immune checkpoint inhibitors, the comparative efficacy of IPI+PD1 versus PD1 monotherapy is unclear. This study compares objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety between these regimens in MUM. Methods: MUM pts treated with PD1 or IPI+PD1 at 15 major melanoma centres (from Australia, Europe, United States and Israel) were included. Demographics, patient and disease characteristics, and clinical outcomes were examined. Univariate and multivariate (MVA) analyses were performed to identify clinical predictors of response and survival. Results: Of 412 MUM pts treated, 150 (36%) had PD1 and 262 (64%) received PD1+IPI. Compared to the PD1 group, PD1+IPI-treated pts were younger (64 vs. 70 years; p<0.001), had higher rate of elevated LDH (44% vs. 31%; p=0.037), and more frequently had prior treatment with tebentafusp (6.5% vs. 1.3%; p=0.031). Median follow-up from commencement of PD1+/-IPI was 4.9 years (95% CI 4.7 – 6.1). ORR was higher in IPI+PD1 group (18%) vs. PD1 (9%) (p=0.008), particularly in males (p=0.009), patients with liver metastases (p=0.018) and with lung metastases (p=0.011), with elevated LDH (p=0.047) and with no prior treatment with tebentafusp (p=0.007). PFS and OS at 1 and 2 years were numerically higher with IPI+PD1 (1- and 2-year PFS: 23% and 15%; 1- and 2-year OS: 63% and 39%) vs. PD1 (1- and 2-year PFS: 17% and 11%; 1- and 2-year OS: 54% and 36%), but these differences were not statistically significant (p>0.05). On MVA, adjusting for predefined variables (age, gender, ECOG PS, LDH, presence/absence of liver/lung metastases, prior treatment with tebentafusp), IPI+PD1 was associated with higher ORR (OR 2.71, 1.30 – 6.05; p=0.01) but not with PFS or OS compared to PD1. Presence of liver metastases (ORR [OR 0.28; 95% CI 0.13 - 0.64], PFS [HR 1.61; 95% CI 1.11 - 2.34], OS [HR 2.02; 95% CI 1.32 - 3.10]), ECOG PS≥2 (PFS [HR 1.82; 95% CI 1.07 - 3.10], OS [HR 2.24; 95% CI 1.25-4.01]), elevated LDH (PFS [HR 1.66; 95% CI 1.30 - 2.11], OS [HR 2.39; 95% CI 1.84-3.10]) and prior tebentafusp treatment (OS [HR 2.36; 95% CI 1.21-4.59]) were also independent predictors of response and/or survival. A higher percentage of pts experienced grade ≥3 immune-related adverse events (irAEs) in the IPI+PD1 group compared to the PD1 group (34% vs 13%, p<0.0001). Most pts ceased treatment due to progression (234, 57%), and more pts stopped due to toxicity in the IPI+PD1 vs. PD1 group (25% vs. 9%, p<0.0001). Conclusions: In pts with MUM, IPI+PD1 demonstrated a higher ORR but did not improve survival compared with PD1 alone. IPI+PD1 was more toxic, leading to early treatment discontinuation in one-quarter of pts. These findings may help guide treatment selection in MUM.
Reduced oxaliplatin exposure in gastrointestinal cancers: A systematic review and meta-analysis.
Silva, L F F , Alsulaiman, Abdullah , Kouli, Ayla , Benkhadra, Khalid, Bekaii-Saab, Tanios S., Schwengber, Wallace Klein , Jamal, Fares , Abidoye, Oluseyi , Bekaii‐Saab, Tanios , Sonbol, Mohamad Bassam

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 3592-3592

10.1200/jco.2026.44.16_suppl.3592 Get It

3592 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent dose-limiting toxicity from oxaliplatin that impairs quality of life in gastrointestinal (GI) cancer patients (pts). While strategies to limit exposure exist, their impact on survival remains debated. We evaluated whether reduced oxaliplatin exposure (ROE) maintains survival while mitigating toxicity. Methods: We conducted a systematic review and meta-analysis (PubMed, Embase, Scopus, Web of Science, EBM Reviews) of studies comparing ROE vs standard-duration oxaliplatin-based chemotherapy in GI cancers. ROE was defined as planned limitation of oxaliplatin exposure, including shortened duration (3-4 months), maintenance-based de-escalation, or stop-and-go strategies. Primary endpoints were disease-free survival (DFS) in curative settings, progression-free survival (PFS) in palliative settings, and overall survival (OS). Secondary endpoints included grade ≥3 CIPN and grade ≥3 adverse events (AEs). Random-effects models used Hartung-Knapp-Sidik-Jonkman correction. Heterogeneity was assessed via I² and Cochran’s Q. Results: 24 studies, comprising 15 randomized controlled trials (RCTs) and 9 retrospective cohorts, were included (N = 30,404 pts; ROE: 13,348; control: 17,056). Settings included adjuvant colorectal cancer (CRC; n = 14), metastatic CRC (mCRC; n = 5), gastric cancer (GC) (adjuvant n = 1, metastatic n = 3), and metastatic pancreatic cancer (PDAC) (n = 1). ROE strategies included shortened duration (n = 14), maintenance (n = 8), and stop-and-go (n = 2). In adjuvant CRC, ROE did not compromise DFS (HR 1.07; 95% CI, 0.98-1.16; p = 0.12; I² = 21.7%), including in high-risk subgroups (HR 1.14; 95% CI, 0.93-1.40; p = 0.14; I² = 38.9%); OS was also not different between groups (HR 1.00; 95% CI, 0.94-1.07; p = 0.89; I² = 0%), including high-risk pts (HR 1.01; 95% CI, 0.93-1.10; p = 0.68; I² = 0%). In mCRC, ROE showed no detriment to PFS (HR 1.11; 95% CI, 0.99-1.25; p = 0.07; I² = 0%) or OS (HR 1.06; 95% CI, 0.92-1.23; p = 0.33; I² = 0%). Similarly, in metastatic gastric cancer, PFS (HR 0.82; 95% CI, 0.34-1.99; p = 0.44; I² = 77.3%) and OS (HR 0.90; 95% CI, 0.67-1.21; p = 0.26; I² = 0%) were comparable. Findings remained concordant after restricting the analysis to only RCTs. Pooled analysis was not feasible for PDAC and adjuvant GC studies, but individual study findings were consistent with the above. ROE significantly reduced the risk of grade ≥3 CIPN (OR 0.32; 95% CI, 0.20-0.53; p < 0.001; I² = 80.6%) and overall grade ≥3 AEs (OR 0.65; 95% CI, 0.50-0.86; p = 0.01; I² = 59.9%). Conclusions: Across GI malignancies, ROE was not associated with inferior DFS, PFS, or OS and was associated with lower rates of severe neurotoxicity and high-grade AEs. These findings support planned limitation of oxaliplatin exposure as a strategy to improve the therapeutic index of oxaliplatin-based chemotherapy across disease settings.
Impact of outpatient CAR T-cell therapy administration on healthcare utilization in patients with hematologic malignancies.
Bowen, Susanna Goggans, Abdallah, Nadine, Corraes, Andre De Menezes Silva, Oyarzabal, Beatriz, Harmsen, W.L., LUNDE, JULIANNE, Coffey, J C, Haugen, Kelsey L., Rosenthal, Allison Claire, Iqbal, Madiha, Kapoor, Prashant , Bennani, Nabila Nora, Johnston, Patrick B., Ansell, Stephen M., Kharfan-Dabaja, Mohamed, Haddad, Tufia C. , Lin, Yi, Paludo, Jonas, Abdallah, Nadine , Pritchett, Joshua C. , Corraes, Andre De Menezes Silva , Oyarzabal, Beatriz A., Lunde, Julianne J. , Haugen, Kelsey, Rosenthal, Allison , Iqbal, Madiha , Alkhateeb, Hassan B. , Johnston, Patrick B. , Ansell, Stephen M. , Kharfan‐Dabaja, Mohamed A. , Paludo, Jonas

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 1503-1503

10.1200/jco.2026.44.16_suppl.1503 Get It

1503 Background: CAR T-cell therapy has revolutionized treatment outcomes in hematological malignancies, but has traditionally required inpatient post-infusion monitoring, which is associated with significant cost and time toxicity. Outpatient CAR T infusion and monitoring has been the standard approach at Mayo Clinic site in Rochester, MN, with demonstrated feasibility and safety (Bansal et al., ASCO 2023). We present data comparing healthcare utilization between CAR T recipients who underwent outpatient remote monitoring and those with traditional inpatient monitoring. Methods: Electronic medical records were retrospectively analyzed for 293 patients who received CAR T-cell therapy for a hematological malignancy at any of the 3 Mayo Clinic sites (MN, AZ, FL) between 2020 and 2024 . Healthcare utilization was compared between patients who received outpatient CAR T with remote patient monitoring in Rochester, MN (N = 125) and those who received inpatient CAR T in the Arizona (n = 90) and Florida (n = 78) sites. Per protocol, patients in the inpatient group underwent mandatory inpatient monitoring for 7 days, with extension per provider discretion. Data was analyzed through Chi-Square and Wilcoxon tests. P values < 0.05 were considered statistically significant. Results: There was no significant difference in baseline sex, age, ethnicity, LDH, platelets, or neutrophils among the 293 patients. Diagnoses included lymphoma (n = 175), multiple myeloma (n = 106), and B-ALL (n = 12). The most common CAR T-cell products used were axicabtagene ciloleucel (n = 138) idecabtagene vicleucel (n = 56), and ciltacabtagene autoleucel (n = 50). Median hospital days were lower in the outpatient group vs the inpatient group at 30 days (4.4 vs 13.3, P < 0.001) and 90 days (4.6 vs 13.6, P < 0.001). ICU admission occurred in 1 outpatient patient ( < 1%) vs 18 inpatient patients (11%) in the first 30 days (P < 0.001). In the first 30 days, 22% of patients in the outpatient group did not require hospitalization, while 56%, 15%, and 6% required 1, 2, and 3 hospitalizations, respectively. Similarly, only 11 (8.8%) patients in the outpatient group had ≥1 ED visit in the first 30 days compared with 32 (20%) pts in the inpatient group (P = 0.009). At 30 days, there was no difference in patient portal use, with 58% of patients using the portal at least once and a median of 1 message in both groups. Within the first 30 days, 53% and 2% of patients in the outpatient group required 1 and 2 outpatient visits, respectively, vs 29% and 2% in the inpatient group (P < 0.001). There was no difference in 30-day mortality (1.6% outpatient vs 2.4% in inpatient) between the 2 groups (P = 1.00) Conclusions: Outpatient CAR T-cell therapy monitoring was associated with significantly fewer hospital days without increased ED visits, ICU stays, portal use, or 30-day mortality. This demonstrates lower healthcare utilization for outpatient CAR-T therapy.
Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma ( RRMM ): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis
Janakiram, Murali , Tan, C. R., Mian, Hira, Huang, C Y, Popat, Rakesh , Martínez‐Lopez, Joaquín, Kastritis, Efsthathios, Chng, Wee-Joo, Kapoor, Prashant , Dave, Mrugakshi, Bal, Susan, Garderet, Laurent, Corraes, Andre De Menezes Silva , Riedhammer, Christine , Steinbrunn, Torsten, Nagarajan, Chandramouli, Einsele, Hermann, Martin, T, Krishnan, Amrita, Lin, Yi, Martínez‐López, Joaquín , Frigault, Matthew J. , Larrea, Carlos Fernández de , Mian, Hira , Tan, Carlyn R , Kastritis, Efstathios , Corona, Magdalene , Martinez-Lopez, Joaquin , Mian, Hira , Janakiram, Murali , Tan, Carlyn , Popat, Rakesh , Chng, Wee Joo , Bal, Susan , Garderet, Laurent , Steinbrunn, Torsten , Nagarajan, Chandramouli

Mayo Clinic

American Journal of Hematology | May 20, 2026 | Volume: 101 | Issue: 8 | Pages: 1928-1937

10.1002/ajh.70376 | PMID 42157444 Get It

ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and toxicity estimates. The median age was 64 years; high‐risk cytogenetics were present in 42%; ECOG ≥ 2 in 22%; 12% had creatinine clearance < 30; and 55% would not have met MonumenTAL‐1 eligibility. Patients received a median of 6 prior lines of therapy, 53% were penta‐refractory, and 75% received prior BCMA therapy. Talquetamab was associated with skin toxicity in 39.7%, nail toxicity in 75.5%, dysgeusia in 60.4%, and oral toxicities in 62.9%, with grade ≥ 3 events uncommon (≤ 4%) and dose interruptions infrequent (9.6% for skin toxicity, 6.9% for dysgeusia, and 4.0% for oral toxicities). These findings underscore the need for improved supportive care for muco‐cutaneous toxicities. In multivariate analysis, only platelet count < 50 (HR 1.8, 95% CI 1.15–2.83) was associated with inferior PFS, while penta‐refractory status, absolute lymphocyte count < 0.4, and prior BCMA‐targeted therapy were not statistically significant. With a median follow‐up of 12.7 months, the overall response rate was 67.6%, median progression‐free survival was 7 months, and 12‐month overall survival was 65%. This study shows that talquetamab efficacy is maintained in a heavily pretreated real‐world population with high prior BCMA exposure and notable comorbidity burden.